The Challenge
Cancer treatment responses vary significantly among patients, even those with the same type and stage of cancer. This heterogeneity poses a major challenge in oncology, as it means that patients may endure treatments that provide little benefit while experiencing significant side effects.
Current methods for predicting treatment response often rely on a limited set of biomarkers or clinical features, and frequently lack sufficient accuracy to guide clinical decision-making with confidence.
Our Approach
Our research leverages advanced machine learning techniques to develop comprehensive predictive models of treatment response. These models integrate multiple data types, including:
- Genomic and transcriptomic profiles that capture the molecular features of tumors
- Radiomics data extracted from medical imaging
- Clinical variables including patient demographics and medical history
- Longitudinal data that tracks changes in tumor characteristics over time
By integrating these diverse data sources, our models can identify complex patterns and relationships that would be impossible to detect using conventional statistical approaches.
Deep Learning Integration
Applying deep neural networks to integrate multi-modal data and extract predictive signatures that indicate likely treatment outcomes.
Explainable AI
Developing interpretable models that not only predict treatment response but also provide insights into the biological factors driving that response.
Dynamic Monitoring
Creating systems that continuously update predictions based on new data collected during treatment, enabling adaptive therapeutic strategies.
Transfer Learning
Leveraging knowledge gained from well-studied cancer types to improve prediction accuracy for rare cancers with limited available data.
Current Research Projects
Immunotherapy Response Prediction
We're developing a comprehensive model to predict patient responses to immune checkpoint inhibitors. This model integrates tumor mutational burden, immune cell infiltration patterns, and PD-L1 expression levels to identify patients likely to benefit from immunotherapy.
Radiogenomics for Targeted Therapy Selection
This project combines radiomics features extracted from CT and MRI scans with genomic data to predict responses to targeted therapies. Our preliminary results suggest that this integrated approach significantly outperforms predictions based on genetic alterations alone.
Longitudinal Response Trajectories
We're applying time-series analysis and recurrent neural networks to model how tumors evolve during treatment. This approach enables us to predict not just initial response but long-term outcomes and the likelihood of developing resistance.
Clinical Impact
Our treatment response prediction research has several potential clinical applications:
- Treatment Selection: Helping clinicians choose the most effective therapy for each patient based on their individual characteristics
- Avoiding Ineffective Treatments: Identifying patients unlikely to respond to specific therapies, sparing them unnecessary side effects and enabling earlier transition to alternative approaches
- Treatment Sequencing: Optimizing the order in which therapies are administered to maximize overall benefit
- Early Response Assessment: Detecting signs of treatment resistance sooner than conventional imaging, allowing for timely intervention
Future Directions
As our research progresses, we plan to explore several exciting directions:
- Developing models that recommend optimal drug combinations and dosing schedules based on patient-specific characteristics
- Incorporating liquid biopsy data to enable non-invasive monitoring of treatment response and early detection of resistance
- Extending our models to predict not just tumor response but also likely side effects, enabling truly personalized benefit-risk assessments
- Creating mobile and cloud-based platforms that make our predictive tools accessible to oncologists worldwide
Collaborations and Partnerships
We're actively seeking partnerships with:
Oncology Centers
To validate our predictive models in diverse clinical settings
Pharmaceutical Companies
To apply our models in drug development and patient stratification
Health Tech Companies
To integrate our predictive algorithms into clinical decision support systems
Research Background
This research area contributes to the growing body of knowledge in AI-powered cancer research. We're currently developing foundational work in this space.
Related Research Areas
Stay Updated
Subscribe to receive updates on our latest research findings and breakthroughs.